Daré Bioscience, Inc. (NASDAQ:DARE) Sees Large Growth in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) saw a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 55,800 shares, a growth of 118.8% from the November 15th total of 25,500 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average trading volume of 40,500 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DARE. Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Friday, November 15th.

Institutional Trading of Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Daré Bioscience Stock Performance

Daré Bioscience stock traded down $0.40 during mid-day trading on Thursday, hitting $3.19. 175,552 shares of the company traded hands, compared to its average volume of 47,804. Daré Bioscience has a one year low of $3.05 and a one year high of $7.56. The stock has a market cap of $27.75 million, a price-to-earnings ratio of -5.41 and a beta of 1.27. The stock has a fifty day moving average price of $3.56 and a 200-day moving average price of $3.77.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.